United States securities and exchange commission logo




                                                                                
                          November 30, 2023

       Daniel Vitt
       Chief Executive Officer
       Immunic, Inc.
       1200 Avenue of the Americas
       Suite 200
       New York, NY 10036

                                                        Re: Immunic, Inc.
                                                            Registration 
Statement on Form S-3
                                                            Filed November 22, 
2023
                                                            File No. 333-275717

       Dear Daniel Vitt:

              This is to advise you that we have not reviewed and will not 
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for 
acceleration. We remind you
       that the company and its management are responsible for the accuracy and 
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of 
action by the staff.

                                                        Please contact Lauren 
Hamill at 303-844-1008 with any questions.



                                                                                
                          Sincerely,

                                                                                
                          Division of Corporation Finance
                                                                                
                          Office of Life Sciences
       cc:                                              Ilan Katz